

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 0 892 643 B1

EUROPEAN PATENT SPECIFICATION

(12)

(45) Date of publication and mention
of the grant of the patent:
19.06.2002 Bulletin 2002/28

(21) Application number: 97916037.1

(22) Date of filing: 20.03.1997

(51) Int Cl.7: A61K 39/395, A61K 38/17
// (A61K39/395, 38:17)

(86) International application number:
PCT/US97/04248

(87) International publication number:
WO 97/34833 (25.09.1997 Gazette 1997/41)

(54) METHODS FOR INHIBITING AN IMMUNE RESPONSE BY BLOCKING THE GP39/CD40 AND
CTLA4/CD28/B7 PATHWAYS AND COMPOSITIONS FOR USE THEREWITH

VERFAHREN ZUR INHIBIERUNG DER IMMUNREAKTION DURCH BLOCKIERUNG DER
GP39/CD40 UND CTLA4/CD28/B7 ROUTEN UND ZUSAMMENSETZUNG ZU DEREN
VERWENDUNG

PROCEDES D'INHIBITION D'UNE REPOSE IMMUNE PAR BLOCAGE DES VOIES DE
GP39/CD40 ET CTLA4/CD28/B7 ET COMPOSITIONS UTILISEES AVEC CEUX-CI

(84) Designated Contracting States:
AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC
NL PT SE

(30) Priority: 20.03.1996 US 13751 P

(43) Date of publication of application:
27.01.1999 Bulletin 1999/04

(80) Divisional application:
01119521.1 / 1 186 300

(73) Proprietors:
• Bristol-Myers Squibb Company
Seattle, WA 98121 (US)
• Emory University
Atlanta, Georgia 30322 (US)

(72) Inventors:
• LARSEN, Christian, P.
Atlanta, GA 30345 (US)
• ARUFFO, Alejandro, A.
Edmonds, WA 98020 (US)
• HOLLENBAUGH, Diane, L.
Seattle, WA 98117 (US)
• LINSLEY, Peter, S.
Seattle, WA 98119 (US)
• LEDBETTER, Jeffrey, A.
Seattle, WA 98117 (US)
• PEARSON, Thomas, C.
Atlanta, GA 30307 (US)

(74) Representative: Kinzebach, Werner, Dr. et al
Patentanwältin
Rechtsanwälte Kinzebach und Partner
Postfach 86 06 49
81633 München (DE)

(56) References cited:
EP-A- 0 555 880 WO-A-92/00092
WO-A-94/01547 WO-A-96/39514
AU-A- 9 476 446 US-A- 5 652 224
US-A- 5 677 165 US-A- 5 683 693
US-A- 5 698 679

- JOURNAL OF CELLULAR BIOCHEMISTRY, SUPPLEMENT, vol. 0, no. 21 part A, 1995, NEW YORK, NY, USA, page 141 XP002037030 N. GRIGGS ET AL.: "Contribution of CD28/CTLA4/B7 and gp39/CD40 costimulation pathways in clonal expansion and functional acquisition of self-reactive T cells."
- SURGICAL FORUM, vol. 47, no. 0, 1996, PHILADELPHIA, PA, USA, pages 427-429, XP002037031 E. ELWOOD ET AL.: "Long-term murine skin allograft survival with perioperative CTLA4-Ig and anti-gp39: The role of CD4+ T cells."
- EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 25, no. 2, February 1995, WEINHEIM, GERMANY, pages 596-603, XP002037032 M. ROY ET AL.: "Studies on the interdependence of gp39 and B7 expression and function during antigen-specific immune responses."

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 0 892 643 B1